[go: up one dir, main page]

NO2699580T3 - - Google Patents

Info

Publication number
NO2699580T3
NO2699580T3 NO12774761A NO12774761A NO2699580T3 NO 2699580 T3 NO2699580 T3 NO 2699580T3 NO 12774761 A NO12774761 A NO 12774761A NO 12774761 A NO12774761 A NO 12774761A NO 2699580 T3 NO2699580 T3 NO 2699580T3
Authority
NO
Norway
Application number
NO12774761A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2699580(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2699580T3 publication Critical patent/NO2699580T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Epoxy Compounds (AREA)
NO12774761A 2014-01-24 2012-04-15 NO2699580T3 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24

Publications (1)

Publication Number Publication Date
NO2699580T3 true NO2699580T3 (el) 2018-02-24

Family

ID=52432834

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12774761A NO2699580T3 (el) 2014-01-24 2012-04-15

Country Status (38)

Country Link
US (18) US9522894B2 (el)
EP (3) EP3744714B1 (el)
JP (5) JP6469711B2 (el)
KR (1) KR102417684B1 (el)
CN (2) CN105980367B (el)
AP (1) AP2016009322A0 (el)
AR (1) AR099177A1 (el)
AU (4) AU2015208932C1 (el)
BR (1) BR112016016224B1 (el)
CA (1) CA2935625C (el)
CL (1) CL2016001889A1 (el)
CR (1) CR20160327A (el)
CY (2) CY1120049T1 (el)
DK (2) DK3323814T3 (el)
DO (1) DOP2016000175A (el)
EA (1) EA032794B1 (el)
ES (2) ES2808060T3 (el)
HK (2) HK1225730B (el)
HR (2) HRP20180116T1 (el)
HU (2) HUE038274T2 (el)
IL (3) IL246614B (el)
LT (2) LT3323814T (el)
MX (1) MX368840B (el)
MY (1) MY194850A (el)
NO (1) NO2699580T3 (el)
NZ (2) NZ734768A (el)
PE (1) PE20161218A1 (el)
PH (1) PH12016501439A1 (el)
PL (2) PL3097086T3 (el)
PT (2) PT3097086T (el)
RS (2) RS56919B1 (el)
SG (2) SG11201606052TA (el)
SI (2) SI3323814T1 (el)
SM (2) SMT201800058T1 (el)
TW (1) TWI690517B (el)
UY (1) UY35963A (el)
WO (1) WO2015110826A1 (el)
ZA (2) ZA201605856B (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (el) 2014-01-24 2018-02-24
WO2018022978A1 (en) * 2016-07-29 2018-02-01 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
AU2019217870A1 (en) * 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
KR20250002710A (ko) * 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
KR20210032431A (ko) * 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
EP3823628A4 (en) * 2018-07-17 2022-04-27 Insmed Incorporated <SMALLCAPS/>? ? ?S? ? ? ? ?CERTAIN (2)- <NS1:I>N</NS1:I>?-[(1 <NS2:I>S</NS2:I>?)-1-CYANO-2-PHENYLETHYL]-1,4 -OXAZEPAN-2-CARBOXAMIDES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
BR112022007623A2 (pt) * 2019-10-23 2022-07-12 Chong Kun Dang Pharmaceutical Corp Composições para prevenir ou tratar doenças pulmonares obstrutivas crônicas (dpoc)
CN116157687A (zh) * 2020-07-20 2023-05-23 英斯梅德股份有限公司 用于提取嗜中性粒细胞丝氨酸蛋白酶以及治疗二肽基肽酶1介导的病症的方法
FI4129989T3 (fi) * 2020-08-26 2024-12-16 Haisco Pharmaceuticals Pte Ltd Dipeptidyylipeptidaasi 1:n estäjänä toimiva nitriilijohdannainen ja sen käyttö
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
WO2022117059A1 (zh) 2020-12-04 2022-06-09 瑞石生物医药有限公司 组织蛋白酶c小分子抑制剂及其医药用途
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN116783189A (zh) * 2021-02-05 2023-09-19 南京明德新药研发有限公司 含1，4-氧杂氮杂环庚烷的并环类衍生物
KR20240004691A (ko) * 2021-04-29 2024-01-11 인스메드 인코포레이티드 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
MX2024005126A (es) * 2021-10-29 2024-05-16 Insmed Inc Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la rinosinusitis cronica.
JP2025504817A (ja) * 2022-01-11 2025-02-19 上海壹典医▲薬▼科技▲開▼▲発▼有限公司 ペプチジルニトリル化合物及びその使用
EP4479059A1 (en) * 2022-02-16 2024-12-25 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
JP2025505824A (ja) * 2022-02-22 2025-02-28 ハイスコ ファーマスーティカル プライベート リミテッド ジペプチジルペプチダーゼ１阻害剤結晶多形体及びその製造方法と用途
EP4484414A1 (en) * 2022-02-22 2025-01-01 Haisco Pharmaceuticals Pte. Ltd. Salt and crystal form of dipeptidyl peptidase inhibitor compound
KR20240150486A (ko) * 2022-02-22 2024-10-15 하이스코 파마수티컬즈 피티이. 엘티디. 질소-함유 헤테로사이클릭 화합물의 제조 방법
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
KR20250023398A (ko) * 2022-06-07 2025-02-18 레이스톤 바이오파마 컴퍼니 리미티드 벤조[c]크로만 화합물의 약학적으로 허용되는 염, 상기 약학적으로 허용되는 염의 다형체 형태 및 용도
KR20250020509A (ko) * 2022-06-07 2025-02-11 레이스톤 바이오파마 컴퍼니 리미티드 벤조[c]크로만 화합물의 다형체, 이의 제조 방법 및 이의 용도
KR20250022023A (ko) 2022-06-13 2025-02-14 알리벡시스 가부시키가이샤 아자사이클로알킬카보닐 환상 아민 화합물
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024081889A1 (en) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
WO2024148308A1 (en) * 2023-01-06 2024-07-11 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
WO2024173556A2 (en) * 2023-02-15 2024-08-22 Insmed Incorporated Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors
TW202442238A (zh) * 2023-03-23 2024-11-01 大陸商西藏海思科製藥有限公司 二肽基肽酶小分子抑制劑的藥物组合物

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
ATE378411T1 (de) 2000-09-08 2007-11-15 Prozymex As Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
RU2004120784A (ru) 2001-12-04 2005-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Замещенные 2-аминоциклоалканкарбоксамиды и их применение в качестве ингибиторов цистеиновой протеазы
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2004106289A1 (en) 2003-05-30 2004-12-09 Prozymex A/S Protease inhibitors
WO2004110988A1 (en) 2003-06-18 2004-12-23 Prozymex A/S Protease inhibitors
KR101504729B1 (ko) 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
EP2017620A3 (en) 2004-04-28 2009-04-22 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
NZ552208A (en) 2004-06-29 2008-11-28 Nycomed Danmark Aps Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
JP5704785B2 (ja) 2004-07-19 2015-04-22 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫抑制のためのｆｌｔ３阻害剤
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
CA2611688A1 (en) 2005-06-30 2007-01-11 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
CA2680173A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
JP2010540526A (ja) 2007-09-25 2010-12-24 ノバルティス アーゲー エアロゾル化されたバンコマイシンのような薬剤での肺障害の処置
WO2009074829A1 (en) * 2007-12-12 2009-06-18 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
KR101805754B1 (ko) 2008-12-08 2017-12-07 먼디파머 인터내셔널 코포레이션 리미티드 단백질 수용체 티로신 키나아제 억제제의 조성물
AU2010231962B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
SG175090A1 (en) * 2009-05-07 2011-11-28 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
WO2011154677A1 (en) 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
TW201302736A (zh) 2011-02-11 2013-01-16 Glaxosmithkline Llc 組織蛋白酶（Ｃａｔｈｅｐｓｉｎ）Ｃ抑制劑
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
CN104114557B (zh) 2012-02-21 2017-10-24 默克专利股份公司 作为syk酪氨酸激酶抑制剂和gcn2丝氨酸激酶抑制剂的8‑取代2‑氨基‑[1,2,4]三唑并[1,5‑a]吡嗪
JP6172143B2 (ja) 2012-04-17 2017-08-02 アステラス製薬株式会社 含窒素二環式芳香族へテロ環化合物
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
WO2014140091A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
ES2845473T3 (es) 2013-03-14 2021-07-26 Boehringer Ingelheim Int (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
EP2970228B1 (en) 2013-03-14 2017-05-10 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
WO2014140081A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
WO2015027039A1 (en) 2013-08-22 2015-02-26 Emory University Devices and methods related to airway inflammation
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
AU2014317048B2 (en) 2013-09-09 2018-05-10 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (el) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
WO2015155709A1 (en) 2014-04-10 2015-10-15 Novartis Ag S1p modulator immediate release dosage regimen
KR20240018675A (ko) 2014-05-15 2024-02-13 인스메드 인코포레이티드 폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법
WO2015180687A1 (en) 2014-05-30 2015-12-03 The University Of Hong Kong Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
WO2016016242A1 (en) 2014-08-01 2016-02-04 Boehringer Ingelheim International Gmbh Substituted oxetanes and their use as inhibitors of cathepsin c
RS59444B1 (sr) 2014-09-12 2019-11-29 Boehringer Ingelheim Int Spirociklični inhibitori katepsina c
EA032104B1 (ru) 2014-11-14 2019-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
EP3265452B1 (en) 2015-03-05 2020-03-04 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
WO2018022978A1 (en) 2016-07-29 2018-02-01 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
AU2019217870A1 (en) * 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
KR20250002710A (ko) 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
EP3823628A4 (en) 2018-07-17 2022-04-27 Insmed Incorporated <SMALLCAPS/>? ? ?S? ? ? ? ?CERTAIN (2)- <NS1:I>N</NS1:I>?-[(1 <NS2:I>S</NS2:I>?)-1-CYANO-2-PHENYLETHYL]-1,4 -OXAZEPAN-2-CARBOXAMIDES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
EP4252844A3 (en) 2019-04-17 2023-12-06 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
WO2020247665A1 (en) 2019-06-05 2020-12-10 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
KR20240004691A (ko) 2021-04-29 2024-01-11 인스메드 인코포레이티드 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드
MX2024005126A (es) 2021-10-29 2024-05-16 Insmed Inc Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la rinosinusitis cronica.
EP4479059A1 (en) 2022-02-16 2024-12-25 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Also Published As

Publication number Publication date
BR112016016224B1 (pt) 2023-02-23
AU2015208932B2 (en) 2017-02-16
JP2022096662A (ja) 2022-06-29
US11655221B2 (en) 2023-05-23
ES2808060T3 (es) 2021-02-25
AU2015208932B8 (en) 2017-03-09
PH12016501439B1 (en) 2017-02-06
LT3097086T (lt) 2018-02-26
US20230069044A1 (en) 2023-03-02
AU2015208932C1 (en) 2017-05-25
AU2017200338B2 (en) 2018-03-01
PE20161218A1 (es) 2016-11-27
US20230278969A1 (en) 2023-09-07
EP3744714B1 (en) 2025-01-15
US20180251436A1 (en) 2018-09-06
US20240336582A1 (en) 2024-10-10
SMT201800058T1 (it) 2018-03-08
DK3323814T3 (da) 2020-08-03
SG10201701056QA (en) 2017-03-30
AU2015208932A1 (en) 2016-07-28
KR102417684B1 (ko) 2022-07-05
US20230062646A1 (en) 2023-03-02
AU2018202956A1 (en) 2018-05-17
US11655224B2 (en) 2023-05-23
SI3097086T1 (en) 2018-04-30
US20230033573A1 (en) 2023-02-02
US11673872B2 (en) 2023-06-13
TW201612167A (en) 2016-04-01
DOP2016000175A (es) 2016-08-15
AR099177A1 (es) 2016-07-06
CY1120049T1 (el) 2018-12-12
CN105980367B (zh) 2019-08-23
US20230025351A1 (en) 2023-01-26
MY194850A (en) 2022-12-19
PL3097086T3 (pl) 2018-04-30
SI3323814T1 (sl) 2020-10-30
CL2016001889A1 (es) 2016-12-09
EA032794B1 (ru) 2019-07-31
CR20160327A (es) 2016-10-20
EP3744714A1 (en) 2020-12-02
IL265611A (en) 2019-05-30
PT3323814T (pt) 2020-08-05
HUE052421T2 (hu) 2021-04-28
US11773069B2 (en) 2023-10-03
US20240132455A1 (en) 2024-04-25
LT3323814T (lt) 2020-10-26
EP3097086B1 (en) 2017-12-13
JP2023156479A (ja) 2023-10-24
US11655222B2 (en) 2023-05-23
MX368840B (es) 2019-10-18
AU2017200338A1 (en) 2017-02-02
AU2019202675B2 (en) 2020-05-28
US20230115170A1 (en) 2023-04-13
KR20160111470A (ko) 2016-09-26
US20150210655A1 (en) 2015-07-30
EA201691375A1 (ru) 2017-01-30
ZA201800431B (en) 2019-09-25
US11680049B2 (en) 2023-06-20
ZA201605856B (en) 2020-02-26
JP6804570B2 (ja) 2020-12-23
US20210238152A1 (en) 2021-08-05
AU2019202675A1 (en) 2019-05-16
JP2019070029A (ja) 2019-05-09
EP3323814A1 (en) 2018-05-23
HK1255870A1 (zh) 2019-08-30
JP7157791B2 (ja) 2022-10-20
US11814359B2 (en) 2023-11-14
JP7336563B2 (ja) 2023-08-31
PH12016501439A1 (en) 2017-02-06
US11117874B2 (en) 2021-09-14
US9815805B2 (en) 2017-11-14
JP2017503832A (ja) 2017-02-02
EP3323814B1 (en) 2020-05-13
PL3323814T3 (pl) 2020-10-19
AU2015208932A8 (en) 2017-03-09
RS56919B1 (sr) 2018-05-31
UY35963A (es) 2015-07-31
EP3097086A1 (en) 2016-11-30
US20230116721A1 (en) 2023-04-13
US10287258B2 (en) 2019-05-14
US10669245B2 (en) 2020-06-02
RS60639B1 (sr) 2020-09-30
AP2016009322A0 (en) 2016-07-31
US12054465B2 (en) 2024-08-06
US20230028726A1 (en) 2023-01-26
NZ722063A (en) 2017-09-29
US20170057938A1 (en) 2017-03-02
JP2021046423A (ja) 2021-03-25
PT3097086T (pt) 2018-02-21
CN105980367A (zh) 2016-09-28
MX2016009349A (es) 2016-10-13
US11673871B2 (en) 2023-06-13
DK3097086T3 (en) 2018-02-05
JP6469711B2 (ja) 2019-02-13
BR112016016224A2 (el) 2017-08-08
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
SG11201606052TA (en) 2016-08-30
CN110483492B (zh) 2023-07-21
CY1123391T1 (el) 2021-12-31
CN110483492A (zh) 2019-11-22
TWI690517B (zh) 2020-04-11
AU2018202956B2 (en) 2019-05-09
ES2658516T3 (es) 2018-03-12
WO2015110826A1 (en) 2015-07-30
US20200017455A1 (en) 2020-01-16
CA2935625A1 (en) 2015-07-30
US9522894B2 (en) 2016-12-20
SMT202000433T1 (it) 2020-09-10
CA2935625C (en) 2022-10-18
US11667615B2 (en) 2023-06-06
IL252836A0 (en) 2017-08-31
US20230250071A1 (en) 2023-08-10
HK1225730B (zh) 2017-09-15
US11655223B2 (en) 2023-05-23
US20230085620A1 (en) 2023-03-23
HRP20201147T1 (hr) 2020-12-11
US20200247765A1 (en) 2020-08-06
HRP20180116T1 (hr) 2018-03-23
NZ734768A (en) 2022-09-30
JP7628587B2 (ja) 2025-02-10

Similar Documents

Publication Publication Date Title
BR112014021090A2 (el)
BR112014017635A2 (el)
BR112014017614A2 (el)
BR112014017625A2 (el)
BR112014017659A2 (el)
BR112014017646A2 (el)
BR112014017638A2 (el)
BR112014020246A2 (el)
BR112014019371A2 (el)
BR112014017755A2 (el)
BR112014017634A2 (el)
BR112014017609A2 (el)
BR112014017644A2 (el)
BR112014018739A2 (el)
BR112014017618A2 (el)
BR112014017647A2 (el)
BR112014017630A2 (el)
BR112014017652A2 (el)
BR112014018617A2 (el)
BR112014017631A2 (el)
BR112014017623A2 (el)
BR112014017621A2 (el)
BR112014017622A2 (el)
BR112014017627A2 (el)
BR112014017641A2 (el)